Efficacy and Safety of SPN-812 (Extended-Release Viloxazine) in Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis
This meta-analysis of five randomized controlled trials involving 1,619 pediatric patients (ages 6-17) demonstrates that SPN-812 at doses of 100, 200, and 400 mg/day significantly improved ADHD symptoms compared to placebo on multiple validated rating scales. SPN-812 at 300 mg/day showed favorable safety profiles with no increased risk of serious adverse events like syncope, though higher doses were associated with increased somnolence and appetite suppression.
